A Randomized Trial to Assess Safety and Immunogenicity of Alternative Formulations of a Quadrivalent Meningococcal (A, C, Y, and W-135) Tetanus Protein Conjugate Vaccine in Toddlers

Pediatric Infectious Disease Journal

Volumn 31, Issue 1, 2012, Pages e15-e23

  McVernon, Jodie ^a   Nolan, Terry ^a   Richmond, Peter ^a   Reynolds, Graham ^a   Nissen, Michael ^a   Lambert, Stephen B ^a   Marshall, Helen ^a   Papa, Thomas ^a   Rehm, Christine ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Infant; Meningococcal; Randomized controlled trial; Tetravalent meningococcal vaccine; Vaccines

Indexed keywords

MENINGOCOCCUS VACCINE; TETRAMEN T; UNCLASSIFIED DRUG;

ANOREXIA; ARTICLE; CHILD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FEVER; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFANT; INJECTION SITE REACTION; IRRITABILITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATHOLOGICAL CRYING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SERUM BACTERICIDAL ANTIBODY ASSAY; SIDE EFFECT; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VACCINATION; VOMITING;

ANIMALS; ANTIBODIES, BACTERIAL; AUSTRALIA; DOUBLE-BLIND METHOD; HUMANS; INFANT; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP A; NEISSERIA MENINGITIDIS, SEROGROUP C; NEISSERIA MENINGITIDIS, SEROGROUP W-135; NEISSERIA MENINGITIDIS, SEROGROUP Y; RABBITS; SERUM BACTERICIDAL ANTIBODY ASSAY; TETANUS TOXOID; TREATMENT OUTCOME; VACCINATION; VACCINES, CONJUGATE;

EID: 84855465317     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31823e1e34     Document Type: Article

References (28)

1. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369:2196-2210.
2. Tapsall J. Annual report of the Australian meningococcal surveillance programme, 2007—amended. Commun Dis Intell. 2009;33:1-9.
3. Ramsay M, Kaczmarski E, Rush M, et al. Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales. Commun Dis Rep CDR Rev. 1997;7:R49-R54.
4. Booy R, Jelfs J, El Bashir H, et al. Impact of meningococcal C conjugate vaccine use in Australia. Med J Aust. 2007;186:108-109.
5. Simpkins D, Wood N, Jelfs J, et al. Modern trends in mortality from meningococcal disease in Australia. Pediatr Infect Dis J. 2009;28:1119-1120.
6. Campbell H, Andrews N, Borrow R, et al. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol. 2010;17:840-847.
7. Maiden MC, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet. 2002;359:1829-1831.
8. Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines. 2009;8:851-861.
9. Rosenstein N, Perkins B, Stephens D, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis. 1999:1894-1901.
10. Hahne SJ, Gray SJ, Jean F, et al. W135 meningococcal disease in England and Wales associated with Hajj 2000 and 2001. Lancet. 2002;359:582-583.
11. Broker M, Veitch K. Quadrivalent meningococcal vaccines: hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine. Travel Med Infect Dis. 2010;8:47-50.
12. Kimmel SR. Using the tetravalent meningococcal polysaccharide-protein conjugate vaccine in the prevention of meningococcal disease. Ther Clin Risk Manag. 2008;4:739-745.
13. Australian Government Department of Health and Ageing. The Australian Immunisation Handbook. 9th ed. Canberra, Australia: Australian Government Department of Health and Ageing; 2008.
14. Goldschneider I, Gotschlich E, Artenstein M. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;127:1307-1323.
15. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003;10:780-786.
16. Borrow R, Andrews N, Goldblatt D, et al. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun. 2001;69:1568-1573.
17. Reisinger KS, Baxter R, Block SL, et al. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin Vaccine Immunol. 2009;16:1810-1815.
18. Jackson LA, Jacobson RM, Reisinger KS, et al. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J. 2009;28:86-91.
19. Black S, Klein NP, Shah J, et al. Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age. Vaccine. 2010;28:657-663.
20. Menactra (Meningococcal [groups A, C, Y and W-135] polysaccharide diphtheria toxoid conjugate vaccine) for intramuscular injection [Prescribing Information, v0.33]. Philadelphia, PA: Sanofi Pasteur;, 2011.
21. Macneil JR, Cohn AC, Zell ER, et al. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatr Infect Dis J. 2011;30:451-455.
22. De Wals P, Deceuninck G, Lefebvre B, et al. Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada. Pediatr Infect Dis J. 2011;30:566-569.
23. Halperin SA, Diaz-Mitoma F, Dull P, et al. Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers. Eur J Clin Microbiol Infect Dis. 2010;29:259-267.
24. Perrett KP, Snape MD, Ford KJ, et al. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr Infect Dis J. 2009;28:186-193.
25. Knuf M, Kieninger-Baum D, Habermehl P, et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine. 2010;28:744-753.
26. Vesikari T, Karvonen A, Bianco V, et al. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial. Vaccine. 2011;29:4274-4284.
27. Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. Vaccine. 2011;29:4264-4273.
28. Richmond P, Borrow R, Goldblatt D, et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis. 2001;183:160-163.